What is Xcovery?
Xcovery operates at the intersection of advanced molecular science and patient-centric oncology care. The company specializes in the development of targeted therapies designed to mitigate the toxicity profiles often associated with traditional cancer treatments. By focusing on high-unmet medical needs, Xcovery aims to improve the quality of life for patients while simultaneously enhancing the efficacy of therapeutic interventions. Their market position is defined by a robust research infrastructure that bridges the gap between early-stage discovery and clinical-grade manufacturing, positioning them as a critical player in the evolution of precision medicine.
How much funding has Xcovery raised?
Xcovery has raised a total of $48.9M across 8 funding rounds:
Series A
$2.4M
Series B
$6M
Debt
$2.1M
Multiple Rounds
$38.1M
Debt
$350K
Series A (2011): $2.4M, investors not publicly disclosed
Series B (2012): $6M, investors not publicly disclosed
Debt (2013): $2.1M, investors not publicly disclosed
Series C (2014): $2.4M, investors not publicly disclosed
Series D (2014): $15M backed by Brace Pharma and EMS S/A
Debt (2014): $675K, investors not publicly disclosed
Private Equity (2014): $20M led by Betta Pharmaceuticals
Debt (2020): $350K supported by PPP
Key Investors in Xcovery
Betta Pharmaceuticals
A leading Chinese pharmaceutical firm specializing in the discovery and commercialization of innovative oncology products, including targeted therapies for lung cancer.
Brace Pharma
An investment firm dedicated to supporting life-changing medicines and innovative therapies that address significant unmet medical needs.
EMS S/A
A prominent Brazilian pharmaceutical company and distributor with a long-standing history of supporting healthcare advancements.
What's next for Xcovery?
Looking ahead, Xcovery is poised to leverage its recent capital infusion to accelerate its late-stage clinical development programs. The strategic focus remains on transitioning promising small-molecule and biologic candidates through the regulatory pipeline. As the company continues to refine its therapeutic portfolio, the emphasis will likely shift toward scaling manufacturing capabilities and expanding commercial partnerships. By maintaining a disciplined approach to R&D, Xcovery is well-positioned to address the evolving demands of the oncology community, ultimately aiming to deliver life-changing agents that offer greater dignity and longevity to patients worldwide.
See full Xcovery company page
